Natural anti-glycan antibodies (NAGA) (NAGA)

Natural anti-glycan antibodies (NAGAs) are a diverse population of endogenous immunoglobulins that recognize and bind to specific carbohydrate structures, or glycans, found on the surfaces of cells, proteins, and pathogens (Huflejt et al., 2009). These antibodies, which include IgM, IgG, and IgA isotypes, are a fundamental part of the immune system's first line of defense, offering protection against various bacteria, viruses, and parasites that display foreign glycan motifs. A well-known example is the anti-Gal antibody, which recognizes the alpha-galactose epitope and is the primary mediator of hyperacute rejection in xenotransplantation (Macher & Galili, 2008). Beyond their protective roles, these antibodies are implicated in the development of autoimmune diseases, such as Guillain-Barré syndrome, where they mistakenly target self-glycans on neural tissues. In oncology, the presence and levels of specific anti-glycan antibodies can serve as important biomarkers for cancer progression and the presence of tumor-associated carbohydrate antigens (Padler-Karavani et al., 2008). Clinical interventions often aim to modulate these antibodies through B-cell depletion, plasmapheresis, or the administration of intravenous immunoglobulins to prevent adverse immune reactions in transplant and autoimmune settings.

Other names

Endogenous anti-glycan antibodiesAnti-carbohydrate antibodiesAGANatural antibodiesAnti-glycan immunoglobulins

Therapeutic strategies targeting these antibodies include the depletion of antibody-producing B-cells and plasma cells, enzymatic cleavage of circulating immunoglobulins to abolish effector functions, and the use of intravenous immunoglobulins to neutralize or downregulate the endogenous antibody repertoire (Macher & Galili, 2008; New et al., 2016).